Literature DB >> 35137337

Preventing the Progression of Episodic Migraine to Chronic Migraine with Acute Treatment Optimization.

Deena E Kuruvilla1, Tanya Bilchik2.   

Abstract

PURPOSE OF REVIEW: To evaluate the evidence regarding acute migraine treatment optimization to prevent the progression of episodic migraine to chronic migraine. This review also provides a summary of evidence-based acute migraine treatments and how to tailor a regimen based on an individual patient's needs. RECENT
FINDINGS: Several acute migraine treatments have been food and drug administration (FDA)-approved since 2020. This review summarizes pain freedom data at 2 h for these medications and devices and examines the classic acute migraine treatments. This review presents the existing data about acute treatment optimization and its preventive role in the progression of episodic migraine to chronic migraine. We present updated clinical trial efficacy endpoints from the American Headache Society (AHS) and the FDA and review the evidence for acute migraine treatments currently available in clinical practice.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Acute treatment; Headache; Migraine

Mesh:

Year:  2022        PMID: 35137337     DOI: 10.1007/s11916-022-01022-0

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  1 in total

1.  Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials.

Authors:  Susan Hutchinson; David W Dodick; Christina Treppendahl; Nathan L Bennett; Sung Yun Yu; Hua Guo; Joel M Trugman
Journal:  Neurol Ther       Date:  2021-02-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.